Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T57585
(Former ID: TTDI01571)
|
|||||
Target Name |
Chloride channel unspecific (ClC)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 3 Target-related Diseases | + | ||||
1 | Chronic obstructive pulmonary disease [ICD-11: CA22] | |||||
2 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
3 | Brain cancer [ICD-11: 2A00] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
1 | 131I-TM-601 | Drug Info | Phase 2 | Glioma | [2] | |
2 | Lancovutide | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [3], [4] | |
3 | TM-601 | Drug Info | Phase 2 | Solid tumour/cancer | [5] | |
4 | BLZ-100 | Drug Info | Phase 1/2 | Glioma | [6] | |
Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
1 | GR-213487 | Drug Info | Discontinued in Phase 2 | Cystic fibrosis | [7] | |
2 | TgAAV-CFTR | Drug Info | Discontinued in Phase 2 | Cystic fibrosis | [8] | |
3 | Endovion | Drug Info | Terminated | Solid tumour/cancer | [9], [10] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Inhibitor | [+] 3 Inhibitor drugs | + | ||||
1 | 131I-TM-601 | Drug Info | [11] | |||
2 | TM-601 | Drug Info | [5] | |||
3 | BLZ-100 | Drug Info | [6] | |||
Modulator | [+] 3 Modulator drugs | + | ||||
1 | Lancovutide | Drug Info | [12] | |||
2 | GR-213487 | Drug Info | [13] | |||
3 | TgAAV-CFTR | Drug Info | [14] | |||
Antagonist | [+] 1 Antagonist drugs | + | ||||
1 | Endovion | Drug Info | [15] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Haemonchus contortus: selection at a glutamate-gated chloride channel gene in ivermectin- and moxidectin-selected strains. Exp Parasitol. 1998 Sep;90(1):42-8. | |||||
REF 2 | ClinicalTrials.gov (NCT00114309) 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma. U.S. National Institutes of Health. | |||||
REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 841). | |||||
REF 4 | ClinicalTrials.gov (NCT00671736) Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis. U.S. National Institutes of Health. | |||||
REF 5 | NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21. | |||||
REF 6 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||||
REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010993) | |||||
REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011201) | |||||
REF 9 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4273). | |||||
REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013896) | |||||
REF 11 | Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6. | |||||
REF 12 | Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother. 2011 Jan;45(1):49-59. | |||||
REF 13 | EP patent application no. 1336602, Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases. | |||||
REF 14 | Novel molecular approaches to cystic fibrosis gene therapy. Biochem J. 2005 April 1; 387(Pt 1): 1-15. | |||||
REF 15 | Inhibition of the endogenous volume-regulated anion channel (VRAC) in HEK293 cells by acidic di-aryl-ureas. J Membr Biol. 2003 Nov 15;196(2):83-94. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.